Commentary
Video
Dr Mayer on Niraparib Plus Dostarlimab in ER+ BRCA/PALB2-Mutated Breast Cancer
Erica L. Mayer, MD, MPH, discusses findings with neoadjuvant niraparib plus dostarlimab in ER-positive, HER2-negative, BRCA/PALB2-mutated breast cancer.
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School, discusses findings with the use of neoadjuvant niraparib (Zejula) plus dostarlimab-gxly (Jemperli) from the estrogen receptor (ER)–positive, HER2-negative, BRCA/PALB2-mutated breast cancer cohort of the phase 2 TBCRC 056 trial (NCT04584255).
Related Videos
Related Content
